PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

PR Newswire

prLean Left

5h ago

Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancertranslating…

Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved progression-free survival and response rates SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli…

Factuality

70/100

Political Bias

Lean Left

Ownership

Cision

Country

USA

Region

North America

Language

English

Keywords#III TAISHAN-302#Phase III#TAISHAN-302 Trial#Survival#Tam-Peli

Read Original ↗

Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer | Pulse Aggregator